Lose weight & keep it off for adults and children aged ≥12 years with obesity, or some adults with overweight and weight-related medical problems.

Wegovy ® is the only GLP-1 RA proven to sustain ~15% mean weight loss at 2 years

Wegovy (semaglutide) injection 2.4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or …

For adults with obesity or some adults with overweight and weight-related medical problems, along with a reduced calorie diet and increased physical activity. If you've struggled with your …

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest …

Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli...

Jan 17, 2025 · In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 …

Jan 21, 2025 · Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for.

May 14, 2024 · Novo Nordisk ’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of …

May 23, 2023 · In the study, patients who received a 50 mg daily dose of the treatment lost an average of 15.1% of their weight over 68 weeks, compared with a 2.4% average weight loss …